Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 1.00 [0.73, 1.37] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | crucial | - |
progression or deaths (PFS) | 1.25 [0.94, 1.66] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
objective responses (ORR) | 1.24 [0.24, 6.50] | | > 1 | | 0% | 1 study (1/-) | 59.8 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
AE (any grade) | 1.52 [0.42, 5.53] | | < 1 | | 0% | 1 study (1/-) | 26.4 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.15 [0.67, 1.97] | | < 1 | | 0% | 1 study (1/-) | 30.3 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 1.12 [0.21, 5.90] | | < 1 | | 0% | 1 study (1/-) | 44.7 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 2.72 [1.15, 6.39] | | < 1 | | 0% | 1 study (1/-) | 1.1 % | NA | not evaluable | | non important | - |
SAE (any grade) | 2.26 [1.24, 4.14] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 2.73 [1.26, 5.89] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.74 [0.19, 2.79] | | < 1 | | 0% | 1 study (1/-) | 67.3 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.85 [0.50, 1.44] | | < 1 | | 0% | 1 study (1/-) | 72.7 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.89 [0.08, 9.99] | | < 1 | | 0% | 1 study (1/-) | 53.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Dyspnoea TRAE (grade 3-4) | 0.89 [0.08, 9.99] | | < 1 | | 0% | 1 study (1/-) | 53.6 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 1.81 [0.20, 16.42] | | < 1 | | 0% | 1 study (1/-) | 30.1 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
hepatitis (Autoimmune) AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Abdominal pain AE (grade 3-4) | 0.29 [0.05, 1.77] | | < 1 | | 0% | 1 study (1/-) | 90.9 % | NA | not evaluable | | non important | - |
Acute kidney injury AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 2.31 [0.49, 10.78] | | < 1 | | 0% | 1 study (1/-) | 14.5 % | NA | not evaluable | | non important | - |
Arthralgia AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 3.22 [0.39, 26.58] | | < 1 | | 0% | 1 study (1/-) | 14.1 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Colitis AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 0.44 [0.06, 3.19] | | < 1 | | 0% | 1 study (1/-) | 79.0 % | NA | not evaluable | | non important | - |
Dermatitis acneiform AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 1.89 [0.68, 5.22] | | < 1 | | 0% | 1 study (1/-) | 11.1 % | NA | not evaluable | | non important | - |
Dysgeusia AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
Dysphonia AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 0.49 [0.17, 1.40] | | < 1 | | 0% | 1 study (1/-) | 90.9 % | NA | not evaluable | | non important | - |
Guillain-Barré syndrome AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
Headache AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
Hypertension AE (grade 3-4) | 0.08 [0.02, 0.37] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Increased ALT AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
Infusion-related reaction AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Intestinal perforation AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
Mucosal inflammation AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Myalgia AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) | 0.02 [0.00, 0.39] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
Peripheral neuropathy AE (grade 3-4) | 0.22 [0.01, 6.66] | | < 1 | | 0% | 1 study (1/-) | 80.4 % | NA | not evaluable | | non important | - |
Peripheral oedema AE (grade 3-4) | 1.80 [0.08, 40.29] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Pneumonitis AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 6.47 [0.36, 115.44] | | < 1 | | 0% | 1 study (1/-) | 10.4 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 1.59 [0.32, 7.82] | | < 1 | | 0% | 1 study (1/-) | 28.6 % | NA | not evaluable | | non important | - |
Rash maculopapular AE (grade 3-4) | 0.44 [0.03, 7.19] | | < 1 | | 0% | 1 study (1/-) | 71.4 % | NA | not evaluable | | non important | - |
Sepsis AE (grade 3-4) | 0.44 [0.06, 3.19] | | < 1 | | 0% | 1 study (1/-) | 79.0 % | NA | not evaluable | | non important | - |
Stomatitis AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.89 [0.03, 26.90] | | < 1 | | 0% | 1 study (1/-) | 52.6 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 0.45 [0.01, 22.65] | | < 1 | | 0% | 1 study (1/-) | 65.4 % | NA | not evaluable | | non important | - |